Cancer drugs that decrease cardiomyocyte viability induce cellular stress. by E. Renee Matthews (18071587)

Loss of nsp14-ExoN activity decreases recombination frequency and alters recombination junction patterns across the genome. by Jennifer Gribble (10005444)

NEMO knockout murine dermal fibroblasts show a decreased nuclear translocation of p65. by Patrick Meyer (3395285)

Decreased pd-FX levels upon gadolinium chloride treatment. by Mohamad Kurdi (133248)

Recombinant SFRP3 decreases migration and invasion of melanoma cells. by Elin J. Ekström (225100)

Decreased reductase activity and increased round body formation in the <i>gpsA</i> mutant. by Dan Drecktrah (36180)

Decrease in optical density of <i>gerP</i> mutants in L-alanine and inosine. by Katherine A. Carr (259428)

“…a<p>Spores were incubated in 0.5 mM L-alanine and 1 mM inosine. ∼65% decrease in OD₆₀₀ represents ∼100% germination. …”

HO-1 overexpression decreases Nox4 activity in C-20/A4 chondrocytes. by Francis Rousset (424375)

Treatment with anti-JAM-C antibody decreases the T-cell response by Gaby Palmer (636)

PF treatment decreases the levels of IL-1β(A) and TNFα(B) in plasma. by Ruo-Bing Guo (298949)

miR-200b is sufficient to decrease tumor growth. by LaTanya V. Williams (504683)

“…PC3-ctrl or PC3 miR-200b cells were seeded at 3000 cells per well in a 96-well plate. Absorbance was measured at indicated time points using a Biorad Model 680 microplate reader. …”

Plakoglobin decreases <i>in vitro</i> cell growth and proliferation. by Zackie Aktary (481667)

Nicotinamide decreases BAL PMNs but causes significant hypoxemia in VILI. by Heather D. Jones (476855)

CaA decreases the CSCs-like properties of malignant HaCaT cells by p38. by Ye Yang (297214)

Treatment with rSFRP4 results in decreased Wnt signalling. by Caroline E. Ford (289563)

“…Results represent the average of 3 experiments and bars represent the standard deviation (s.d) of the mean. *<i>P</i><0.05. (<b>B</b>) Representative immunoblots showing increased SFRP4 and decreased nuclear β-catenin protein expression in OVCAR3 cells following 72 hours treatment with rSFRP4 (5 µg/ml). …”

Fig 2 - by Marc S. Penn (16624541)

Subjects:

Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”

Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”

Aβ42 increases the level of tau in the cytosol and decreases the level of microtubule-bound tau. by Kanae Ando (1951501)

DC depletion decreases bacterial load upon bacterial infection. by Stella E. Autenrieth (182751)